These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37517413)

  • 1. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
    Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Oh S; Klencke BJ; Yu J; Donahue R; Kawashima J; Mesa R
    Lancet Haematol; 2023 Sep; 10(9):e735-e746. PubMed ID: 37517413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
    Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
    Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
    Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U
    Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
    Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
    J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
    Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
    Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.
    Shimoda K; Komatsu N; Matsumura I; Ikeda K; Hino M; Hidaka M; Maeda Y; Kondo T; Fujisaki T; Shoshi K; Azuma K; Fukushima R; Kawashima J; Kosugi H
    Int J Hematol; 2024 Sep; 120(3):314-324. PubMed ID: 39110143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
    Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
    Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
    Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
    Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
    Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
    Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].
    Kosugi H
    Rinsho Ketsueki; 2024; 65(8):798-809. PubMed ID: 39231711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
    Mesa RA; Hudgens S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan DP; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins A; Leahy MF; Deheshi S; Donahue R; Klencke BJ; Verstovsek S
    Cancer Med; 2023 May; 12(9):10612-10624. PubMed ID: 37021939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.
    Masarova L; Verstovsek S; Liu T; Rao S; Sajeev G; Fillbrunn M; Simpson R; Li W; Yang J; Le Lorier Y; Gorsh B; Signorovitch J
    Future Oncol; 2024; 20(30):2259-2270. PubMed ID: 39072442
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
    Harrison CN; Mesa R; Talpaz M; Al-Ali HK; Xicoy B; Passamonti F; Palandri F; Benevolo G; Vannucchi AM; Mediavilla C; Iurlo A; Kim I; Rose S; Brown P; Hernandez C; Wang J; Kiladjian JJ
    Lancet Haematol; 2024 Oct; 11(10):e729-e740. PubMed ID: 39265613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
    Kiladjian JJ; Vannucchi AM; Gerds AT; Gupta V; Verstovsek S; Egyed M; Platzbecker U; Mayer J; Grosicki S; Illés Á; Woźny T; Oh ST; McLornan D; Kirgner I; Yoon SS; Harrison CN; Klencke B; Huang M; Kawashima J; Mesa R
    Hemasphere; 2023 Nov; 7(11):e963. PubMed ID: 37908862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.